TEXT-EXTRACT 2 filename2.txt United States securities and exchange commission logo November 5, 2021 Matthew Gline Chief Executive Officer and Director Roivant Sciences Ltd. Suite 1, 3rd Floor 11-12 St. James s Square London SW1Y 4LB United Kingdom Re: Roivant Sciences Ltd. Registration Statement on Form S-1 Filed October 29, 2021 File No. 333-260619 Dear Mr. Gline: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Derek J. Dostal